Erasca Presents Preclinical Data Supporting Clinical Development Of Potentially Best-In-Class Programs ERAS-007, ERAS-601, And ERAS-3490 at 2022 AACR Annual Meeting
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced
Stocks That Hit 52-Week Lows On Friday
During Friday's morning session, 234 stocks hit new 52-week lows.
Erasca Announces Clinical Trial Collaboration And Supply Agreement With Eli Lilly And Company To Evaluate ERAS-007 And Cetuximab Combination
ERAS-007, a potential best-in-class ERK1/2 inhibitor, is being evaluated clinically in combination with encorafenib and cetuximab in patients with BRAF V600E-mutant mCRC
Erasca previously signed a clinical trial
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's morning trading, 87 companies set new 52-week lows.
Erasca Announces Presentation Of Preclinical Data On ERAS-801 At AACR Conference On Brain Cancer
Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the